Pharvaris N.V. Consensus Price Target Raised 20.08% to $59.77
The average one-year price target for Pharvaris N.V. (NASDAQGS:PHVS) has been revised to $59.77 / share, up 20.08% from the prior estimate of $49.78 dated August 25, 2026. These figures are aggregate analyst targets compiled by Fintel and do not constitute a recommendation by Fintel.
The latest analyst targets range from a low of $42.42 to a high of $82.95 / share. The mean target of $59.77 is 53.81% above the latest reported closing price of $38.86 / share as of September 14, 2026. The current mean-median gap is $3.47; the current median target is $63.24, which increased from the prior median of $46.92.
This update is part of a consecutive target revision count of 7 in the upward direction. Target history (mean): $59.77 on September 15, 2026; $49.78 on August 28, 2026; $48.55 on August 4, 2026; $47.87 on June 30, 2026. The twelve-month high mean target is $59.77 as of September 15, 2026; the twelve-month low mean target is $33.94 as of September 30, 2025. Target change since the 90-day baseline date of June 8, 2026, is +25.83%.
Pharvaris N.V., based in the Netherlands, is a biopharmaceutical company focused on discovery and development of novel oral therapies for hereditary angioedema (HAE). A key program includes PHA121, an oral bradykinin B2 receptor antagonist.
Recent price changes: +10.24% over one week from a baseline close of $35.25 on September 4, 2026, and +10.59% over one month from a baseline close of $35.14 on August 14, 2026. In its latest earnings report dated August 12, 2026, Pharvaris reported actual EPS of -0.7 versus an estimated EPS of -0.6651; actual revenue was $0.00, matching the estimated $0.00.
Recent analyst actions include Guggenheim maintaining a Buy rating on September 10, 2026. Citizens maintained a Market Outperform rating, RBC Capital maintained an Outperform rating, and Wells Fargo maintained an Overweight rating, all on September 9, 2026. Recommendation trend for the period of September 1, 2026: 21 recommendations — 9 strong buy, 10 buy, 2 hold — positive recommendation percentage 90.5% and hold percentage 9.5%.
Pharvaris operates in the Biotechnology sub-industry of the Health Care sector. Among its peers, PTC Therapeutics saw an upward revision, while BioCryst Pharmaceuticals and Intellia Therapeutics experienced downward revisions to their mean targets.
| Company Name | Target revision | Implied change |
|---|---|---|
| BioCryst Pharmaceuticals | -0.46% | +168.78% |
| Intellia Therapeutics | -8.37% | +112.93% |
| PTC Therapeutics | +1.56% | +53.31% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.